What is JBIO's convertible debt (non-current)?

JBIO (JBIO) reported convertible debt (non-current) of $0 in Q4 2025.

What does convertible debt (non-current) mean?

This represents the portion of long-term debt obligations that can be converted into equity shares at the option of the holder, with a maturity date exceeding one year. It is a common financing tool for growth-stage companies to raise capital while deferring immediate cash interest payments. Investors track this to evaluate long-term solvency and the potential for future equity dilution upon conversion.

JBIO JBIO Convertible Debt (Non-Current)

Convertible Debt (Non-Current) at other companies

CelcuityCELC

$195.57M—

WolfspeedWOLF

$798.3M-73.8%

Esperion TherapeuticsESPR

$97.39M+0.5%

Plug PowerPLUG

$502.77M+97.0%

Twenty One Capital XXI

$484.43M—

ADTRAN Holdings, Inc.ADTN

$193.43M—

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B+318%

Enterprise value$1.28B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleLongTermNotesPayable.

The official record: JBIO’s 10-K, filed March 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's convertible debt (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's convertible debt (non-current)?: JBIO (JBIO) reported convertible debt (non-current) of $0 in Q4 2025.
What does convertible debt (non-current) mean?: This represents the portion of long-term debt obligations that can be converted into equity shares at the option of the holder, with a maturity date exceeding one year. It is a common financing tool for growth-stage companies to raise capital while deferring immediate cash interest payments. Investors track this to evaluate long-term solvency and the potential for future equity dilution upon conversion.